| EPB0244 | Viral suppression in the era of transition to Dolutegravir-based therapy in Cameroon: children at high risk of virological failure | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAB0105 | Virological dynamics among children living with HIV transitioned to a dolutegravir-based regimen in Nigeria | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAB0403 | Vitamin D and calcium intake are associated with bone deficits among adolescents living with HIV in Zambia and Zimbabwe | Oral abstract session with live Q&A | Co-morbidities |
| EPD0739 | Vocational Skills Training – a gateway to empowerment of adolescent girls and young women at risk of acquiring HIV: lessons from Zimbabwe, 2022 | E-poster | Sexualities and sexual cultures: Meanings, identities, norms and communities |
| MOPEC16 | Voluntary medical male circumcision and incident HIV acquisition among men who have sex with men: a randomized controlled trial | Poster exhibition | HIV prevention research |
| EPC0400 | Voluntary Medical Male Circumcision related Adverse Events in South Africa: no room for complacency | E-poster | HIV prevention research |
| EPE0936 | Vulnerability and dissavings among recipients of HIV care in Zimbabwe: a call for social protection integration action | E-poster | HIV and development synergies |
| EPC0513 | W96 results of the OPTICARE program (France), an implementation program to optimize care among vulnerable persons living with HIV (PLWH) in virological failure (VF) | E-poster | Cascades of HIV care and treatment |
| LBEPB13 | Week-96 results of ALLIANCE, a phase 3, randomized, double-blind study comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in treatment-naïve people with both HIV-1 and hepatitis B | E-poster | Co-infections (including opportunistic infections) |
| OAB0203 | Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |